Novocure LimitedNASDAQ: NVCR

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

· Issued by Novocure Limited via Business Wire
Watch Novocure explain itNovoCure Limited (NVCR) Q2 2026 Earnings Call · Replay · Jul 23

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

“The approval of Optune Pax provides a promising new treatment option for locally advanced pancreatic cancer, a disease with an urgent need for effective therapies,” said Makoto Ueno, MD, PhD, Director, Department of Gastroenterology, Kanagawa Cancer Center, Yokohama. “In the Phase 3 PANOVA-3 trial for Optune Pax, there was a statistically significant improvement in overall survival and pain progression was delayed, helping to preserve overall quality of life for people with this disease.”

Optune Pax is a portable medical device that delivers Tumor Treating Fields (TTFields) non-invasively through wearable arrays. TTFields are alternating electric fields that disrupt processes critical for cancer cell division and survival, resulting in cancer cell death without significantly affecting healthy cells.

“The approval of Optune Pax by the Ministry of Health, Labour and Welfare is an important milestone for Novocure in our efforts to improve outcomes for some of the most challenging and aggressive cancers, including advanced pancreatic cancer,” said Hidehito Kotani, Senior Vice President, Head of Asia Pacific, Novocure. “Optune Pax is a fundamentally different treatment for solid tumor cancers and we look forward to bringing this option to healthcare providers and people living with locally advanced pancreatic cancer.”

The MHLW approval of Optune Pax was based on the positive results of the Phase 3 PANOVA-3 trial.

The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma, compared to gem/nab-pac alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields.

In PANOVA-3, Optune Pax was well-tolerated and did not exacerbate gem/nab-pac -related systemic toxicity, no new safety signals were observed, and serious adverse events (SAEs) were comparable between study arms. Most Optune Pax-treated patients experienced the expected device-related skin adverse events (AEs) under the arrays (76.3% of the Optune Pax-treated participants). The majority of these events were mild to moderate (Grade 1-2), with 21 (7.7%) experiencing a Grade ≥3 event.

The results from the Phase 3 PANOVA-3 trial were published in the Journal of Clinical Oncology, available online at https://ascopubs.org/doi/10.1200/JCO-25-00746.

Optune Pax was approved by the U.S. Food and Drug Administration in February 2026 and received a CE Mark in June 2026.

Pancreatic Cancer

According to the World Health Organization (WHO), pancreatic cancer is one of the most lethal cancers and is the fourth most frequent cause of death from cancer in Japan.1 While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing.2 It is estimated that in Japan approximately 46,000 patients are diagnosed with pancreatic cancer each year,3 with a five-year relative survival rate of just 12%.4

Physicians use different combinations of surgery, radiation, and pharmacological therapies to treat pancreatic cancer, depending on the stage of the disease. Unfortunately, most locally advanced pancreatic cancer cases are diagnosed when the cancer is no longer operable, meaning encasement of blood vessels, but no extra-pancreatic disease, leaving few treatment options. The standard of care for locally advanced pancreatic cancer is chemotherapy with or without radiation, and surgery if it is possible.

About Tumor Treating Fields

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multi-mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and it demonstrated enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.

To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit novocure.com/ttfields.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 26, 2026, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

______________________________

1 International Agency for Research on Cancer. 2024. Cancer Today (GLOBOCAN 2022) https://gco.iarc.who.int/today/en/dataviz/tables?mode=cancer&group_populations=1&populations=392&multiple_populations=1&types=1 Accessed on September 1, 2026.

2 American Cancer Society. Cancer Facts & Figures 2025. 1930;(500825). https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf Accessed on September 11, 2026.

3 International Agency for Research on Cancer. 2024. Cancer Today (GLOBOCAN 2022) https://gco.iarc.who.int/today/en/dataviz/tables?mode=cancer&group_populations=1&populations=392&multiple_populations=1&types=0 Accessed on September 1, 2026.

4 Foundation for Promotion of Cancer Research. Cancer Statistics in Japan ─ 2026. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2026_fig_E.pdf Accessed on September 8, 2026.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001277516/en/

Investors: Adam Daney investorinfo@novocure.com

Media: Joachim Horschitz media@novocure.com

Source: Novocure

Attached document

Contents
  1. Cancer Facts & Figures 2025 · page 1
  2. Contents · page 2
  3. Basic Cancer Facts · page 3
  4. What Is Cancer? · page 3
  5. Can Cancer Be Prevented? · page 3
  6. How Many People Alive Today Have Ever Had Cancer? · page 3
  7. How Many New Cases and Deaths Are Expected to Occur in 2025? · page 3
  8. How Much Progress Has Been Made Against Cancer? · page 3
  9. Do Cancer Incidence and Death Rates Vary by State? · page 3
  10. Who Is at Risk of Developing Cancer? · page 3
  11. What Percentage of People Survive Cancer? · page 4
  12. How Is Cancer Staged? · page 4
  13. What Are the Costs of Cancer? · page 4
  14. Selected Cancers · page 5
  15. Breast · page 5
  16. Cancer in Children and Adolescents · page 13
  17. Colon and Rectum · page 15
  18. Kidney and Renal Pelvis · page 16
  19. Leukemia · page 17
  20. Liver · page 18
  21. Lung and Bronchus · page 19
  22. Lymphoma · page 20

Page 1

American Cancer Society

Cancer Facts & Figures 2025

Estimated number of new cancer cases in 2025, excluding basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates are model-based projections and should be interpreted with caution. ©2025, American Cancer Society, Inc. Surveillance and Health Equity Science

Page 2

Contents

Basic Cancer Facts Figure 1. Trends in Age-adjusted Cancer Death Rates by Site, Males, US, 1930-2022 Selected Cancers Breast Figure 2. Trends in Age-adjusted Cancer Death Rates by Site, Females, US, 1930-2022 Table 1. Estimated Number of New Cancer Cases and Deaths by Sex, US, 2025 Table 2. Estimated Number of New Cases for Selected Cancers by State, US, 2025 Table 3. Estimated Number of Deaths for Selected Cancers by State, US, 2025 Table 4. Incidence Rates for Selected Cancers by State, US, 2017-2021 Table 5. Death Rates for Selected Cancers by State, US, 2018-2022 Table 6. Probability (%) of Developing Invasive Cancer During Selected Age Intervals by Sex, US, 2018-2019, 2021 Table 7. Trends in 5-year Relative Survival Rates (%) by Race, US, 1975-2020 Cancer in Children and Adolescents Table 8. Five-year Relative Survival Rates (%) by Stage at Diagnosis, US, 2014-2020 Colon and Rectum Kidney and Renal Pelvis Figure 3. Leading Sites of New Cancer Cases and Deaths – 2025 Estimates Leukemia Liver Lung and Bronchus Lymphoma

Oral Cavity and Pharynx Ovary Pancreas Prostate Skin Thyroid Urinary Bladder Uterine Cervix Uterine Corpus Cancer Disparities

Table 9. Incidence and Mortality Rates for Selected Cancers by

Race and Ethnicity, US Cancer Risk Factors Tobacco Use

29 30 30

Figure 4. Proportion of Cancer Cases and Deaths Attributable to Cigarette Smoking in Adults 30 Years and Older, US, 2019 30

Nutrition and Physical Activity

31

Figure 5. Proportion of Cancer Cases and Deaths Attributable to Excess Body Weight in Adults 30 Years

and Older, US, 2019 The Global Cancer Burden

31 33

Figure 6. Proportion and Number of Cancer Cases or Deaths Attributable to Select Modifiable Risk Factors, 2020-2021 33

The American Cancer Society Sources of Statistics

36 41

American Cancer Society Recommendations for the Early Detection of Cancer in Average-risk Asymptomatic People 44

This publication summarizes current scientific information about cancer. Except when specified, it does not represent the official policy of the American Cancer Society.

©2025, American Cancer Society, Inc. All rights reserved, including the right to reproduce this publication or portions thereof in any form. Email the American Cancer Society Legal department at permissionrequest@cancer.org for permission.

Page 3

Basic Cancer Facts

What Is Cancer?

Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can result in death if untreated. The cause of most cancers is unknown, but some lifestyle factors and inherited genetic mutations can increase risk, either by acting alone or in combination, to initiate and/or promote cancer growth.

Can Cancer Be Prevented?

Excluding non-melanoma skin cancer, at least 40% of newly diagnosed cancers in US adults – about 811,000 cases in 2025 – are potentially avoidable, including the 19% of cancers caused by cigarette smoking, 8% caused by excess body weight, and 5% caused by alcohol consumption. For more information on the proportion of cancers attributable to modifiable risk factors, including infectious agents, see Islami et al 2024. Additionally, screening can help prevent colorectal and cervical cancers by detecting precancerous lesions that can be removed, and can help reduce the risk of death from these cancers, as well as cancers of the breast, lung, and prostate, by detecting cancer early when treatment is usually more successful. For detailed cancer screening guidelines, see page 44.

How Many People Alive Today Have Ever Had Cancer?

More than 18 million Americans with a history of invasive cancer were alive on January 1, 2022, most of whom were diagnosed many years ago, see Miller et al 2022.

How Many New Cases and Deaths Are Expected to Occur in 2025?

Excluding non-melanoma skin cancers, over 2 million new cancer cases are expected to be diagnosed in the US in 2025 and more than 618,000 people will die from the disease (Table 1), the equivalent of about 1,700 deaths per day. Table 2 and Table 3 provide estimated new cancer cases and deaths, respectively, in 2025 by state.

How Much Progress Has Been Made Against Cancer?

Cancer mortality rates are the best measure of progress against cancer because they are less affected by changes in detection practice than incidence (new diagnoses) and survival rates. The age-adjusted cancer death rate rose during most of the 20th century because of the smoking epidemic but has dropped from its peak in 1991 by 34% as of 2022 because of reductions in smoking, advances in treatment, and early detection for some cancers. This translates to nearly 4.5 million fewer cancer deaths during this time than would have occurred if the death rate had remained at its peak. This progress mostly reflects declines in the four most common cancers – lung, colorectal, breast, and prostate (Figure 1 and Figure 2). Over the past decade (2013-2022), the cancer death rate dropped by 1.7% per year.

Do Cancer Incidence and Death Rates Vary by State?

Cancer rates vary substantially across states, with the largest differences for cancers that are most preventable, such as lung cancer. For example, male lung cancer incidence varies by 3.5-fold, from 28 per 100,000 men in Utah to 98 in Kentucky (Table 4). Table 5 provides average annual death rates for selected cancers by state.

Who Is at Risk of Developing Cancer?

Everyone is at risk of developing cancer, although incidence increases greatly with age; 88% of people diagnosed with cancer in the US are 50 years or older, and 59% are 65 or older. In the US, an estimated 40 out of 100 men and 39 out of 100 women will develop cancer during their lifetime (Table 6). However, these probabilities are based on cancer occurrence in the population overall and may differ in individuals because of lifestyle exposures (e.g., smoking, excess body weight), family history, and/or genetic susceptibility.

Cancer Facts & Figures 2025

Page 4

What Percentage of People Survive Cancer?

The 5-year relative survival rate for all cancers combined is 69% for people diagnosed from 2014 to 2020 (Table 7). Relative survival is a measure of life expectancy among cancer patients compared to that among the general population of the same age, race, and sex. Since the early 1960s, 5-year relative survival increased from 39% to 70% among White people and from 27% to 65% among Black people because of advances in treatment and earlier diagnosis for some cancers. Survival varies greatly by cancer type and stage (Table 8), as well as age at diagnosis. For more information about relative survival, see Sources of Statistics on page 41.

How Is Cancer Staged?

Stage describes how much cancer is in the body, usually based on the size or extent of the primary tumor and whether it has spread to nearby lymph nodes or other areas of the body. This report uses a summary staging

system that is standard for descriptive analyses of population-based cancer registry data and particularly useful for tracking trends. According to this system, if cancer is confined to the layer of cells where it began growing, the stage is in situ. If cancer cells have penetrated beyond the original layer of tissue, the cancer has become invasive and is categorized as local, regional, or distant based on the extent of spread. (For a more detailed description of these categories, see the footnotes in Table 8.) Some cancers (such as leukemia and brain tumors) cannot be staged using this system. See www.cancer.org/cancer/diagnosis-staging/staging for more information on cancer staging.

What Are the Costs of Cancer?

The costs of cancer are estimated in several ways, including direct medical costs (total of all health care expenditures) and indirect costs, such as lost earnings due to missed work from illness or premature death. The National Cancer Institute estimated that cancer-related medical costs in the US were $208.9 billion in 2020, which was likely an underestimate because it did not

Show more of the filing

Figure 1. Trends in Age-adjusted Cancer Death Rates by Site, Males, US, 1930-2022

Rates are age adjusted to the 2000 US standard population and exclude deaths in Puerto Rico and other US territories. Due to improvements in classification, site-specific information differs from contemporary data for cancers of the liver, lung and bronchus, and colon and rectum. Data source: US Mortality Volumes 1930 to 1959, US Mortality Data 1960 to 2022, National Center for Health Statistics, Centers for Disease Control and Prevention. ©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

Page 5

account for the growing cost of treatment; for example, the list price for many prescription medicines is more than $100,000 annually. Cancer-related costs to patients are estimated at $21.1 billion, including $16.2 billion in

total out-of-pocket costs and $4.9 billion in patient time costs (travel to/from treatment and waiting for and receiving care).

Selected Cancers

This section provides information on the occurrence, risk factors, symptoms, early detection, and treatment for the most common types of cancer and may have limited relevance for specific subtypes. Incidence trends are based on population-based registry data for cases diagnosed from 1998 through 2021 (covering 99% of the US population) that have been adjusted for delays in reporting; data for 2020 were excluded from trend analysis for improved accuracy based on guidance from the National Cancer Institute (seer.cancer.gov/data/ covid-impact.html). Mortality trends are based on death certificate data from 1975 through 2022 reported to the National Vital Statistics System. See Sources of Statistics on page 41 for more information on data sources and methods.

Breast

New cases and deaths: In the US in 2025, there will be an estimated 316,950 new cases of invasive breast cancer diagnosed in women and 2,800 cases in men, with an additional 59,080 cases of ductal carcinoma in situ (DCIS) diagnosed in women (Table 1; Figure 3). An estimated 42,680 breast cancer deaths (42,170 in women, 510 in men) will occur in 2025.

Incidence trends: Invasive female breast cancer incidence has been increasing since the mid-2000s; from 2012 to 2021, the rate increased by 1% per year overall; 1.4% per year in women younger than 50 years; and by 0.7% per year in those 50 and older. The rising trend is at least in part attributed to changing risk factors, such as

Figure 2. Trends in Age-adjusted Cancer Death Rates by Site, Females, US, 1930-2022

Rates are age adjusted to the 2000 US standard population and exclude deaths in Puerto Rico and other US territories. Due to improvements in classification, site-specific information differs from contemporary data for cancers of the liver, lung and bronchus, colon and rectum, and uterus. aUterus refers to uterine cervix and uterine corpus combined. Data source: US Mortality Volumes 1930 to 1959, US Mortality Data 1960 to 2022, National Center for Health Statistics, Centers for Disease Control and Prevention. ©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

Page 6

Table 1. Estimated Number of New Cancer Cases and Deaths by Sex, US, 2025

Estimated New Cases Both sexesEstimated New Cases MaleEstimated New Cases FemaleEstimated Deaths Both sexesEstimated Deaths MaleEstimated Deaths Female
All sites2,041,9101,053,250988,660618,120323,900294,220
Oral cavity & pharynx59,66042,50017,16012,7709,1303,640
Tongue20,04014,1205,9203,2702,2101,060
Mouth15,7309,0906,6403,3602,0901,270
Pharynx21,64017,8003,8404,5903,630960
Other oral cavity2,2501,4907601,5501,200350
Digestive system362,200201,190161,010174,520100,25074,270
Esophagus22,07017,4304,64016,25012,9403,310
Stomach30,30017,72012,58010,7806,4004,380
Small intestine13,9207,1906,7302,0601,190870
Colon & rectuma154,27082,46071,81052,90028,90024,000
Colon107,32054,51052,810
Rectum46,95027,95019,000
Anus, anal canal, & anorectum10,9303,5607,3702,0307801,250
Liver & intrahepatic bile duct42,24028,22014,02030,09019,25010,840
Gallbladder & other biliary12,6106,0406,5704,4001,9502,450
Pancreas67,44034,95032,49051,98027,05024,930
Other digestive organs8,4203,6204,8004,0301,7902,240
Respiratory system245,700124,700121,000130,20068,34061,860
Larynx13,02010,1102,9103,9103,140770
Lung & bronchus226,650110,680115,970124,73064,19060,540
Other respiratory organs6,0303,9102,1201,5601,010550
Bones & joints3,7702,1501,6202,1901,240950
Soft tissue (including heart)13,5207,6005,9205,4102,9602,450
Skin (excluding basal & squamous)112,69065,74046,95014,1109,5504,560
Melanoma of the skin104,96060,55044,4108,4305,4702,960
Other nonepithelial skin7,7305,1902,5405,6804,0801,600
Breast319,7502,800316,95042,68051042,170
Genital system444,610325,690118,92071,51036,88034,630
Uterine cervix13,36013,3604,3204,320
Uterine corpus69,12069,12013,86013,860
Ovary20,89020,89012,73012,730
Vulva7,4807,4801,7701,770
Vagina & other genital, female8,0708,0701,9501,950
Prostate313,780313,78035,77035,770
Testis9,7209,720600600
Penis & other genital, male2,1902,190510510
Urinary system170,470120,32050,15033,14022,84010,300
Urinary bladder84,87065,08019,79017,42012,6404,780
Kidney & renal pelvis80,98052,41028,57014,5109,5504,960
Ureter & other urinary organs4,6202,8301,7901,210650560
Eye & orbit3,1401,6201,520490270220
Brain & other nervous system24,82014,04010,78018,33010,1708,160
Endocrine system52,14016,45035,6903,4401,6801,760
Thyroid44,02012,67031,3502,2901,0901,200
Other endocrine8,1203,7804,3401,150590560
Lymphoma89,07049,98039,09020,54011,7808,760
Hodgkin lymphoma8,7204,8403,8801,150720430
Non-Hodgkin lymphoma80,35045,14035,21019,39011,0608,330
Myeloma36,11020,03016,08012,0306,5405,490
Leukemia66,89038,72028,17023,54013,50010,040
Acute lymphocytic leukemia6,1003,4502,6501,400720680
Chronic lymphocytic leukemia23,69014,3409,3504,4602,8101,650
Acute myeloid leukemia22,01012,0609,95011,0906,1304,960
Chronic myeloid leukemia9,5605,6103,9501,290740550
Other leukemia5,5303,2602,2705,3003,1002,200
Other & unspecified primary sitesb37,37019,72017,65053,22028,26024,960

Estimates are rounded to the nearest 10; cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. About 59,080 cases of female breast ductal carcinoma in situ and 107,240 cases of melanoma in situ will be diagnosed in 2025. These are model-based estimates and should be interpreted with caution. aDeaths for colon and rectal cancers are combined because a large number of deaths from rectal cancer are misclassified as colon. bMore deaths than cases may reflect a lack of specificity in recording the underlying cause of death on death certificates and/or an undercount in the case estimate. ©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

Page 7

Table 2. Estimated Number of New Cases for Selected Cancers by State, US, 2025

StateAll sitesFemale breastColon & rectumLeukemiaLung & bronchusMelanoma of the skinNon-Hodgkin lymphomaProstateUrinary bladderUterine cervixUterine corpus
Alabama30,0304,9602,6308604,0501,4709805,4401,240230920
Alaska3,67055035011043090150710170a110
Arizona42,5606,9503,2201,4404,2503,7901,7005,3802,0902701,450
Arkansas19,7002,6901,5605902,6609706902,930780150480
California199,98032,86016,0506,00016,33011,1408,28029,6007,2201,4907,480
Colorado29,0205,2502,1301,0302,5202,0601,2104,4001,220190910
Connecticut23,9203,7901,6307702,7407809903,5701,150110860
Delaware7,6801,2105002209204102901,460350a260
Dist. of Columbia3,1405802308033010011038080a140
Florida171,96023,92012,3306,98018,53010,2907,55026,9208,0701,1605,720
Georgia66,21010,1805,1601,9806,8103,5202,15010,3602,3904602,000
Hawaii9,0401,5108202708805703301,16029060440
Idaho11,8201,8208604301,1209605001,97058070310
Illinois78,87012,1606,1102,4309,2704,2203,09012,3503,2204902,780
Indiana42,1506,4703,4101,3306,1202,3001,6006,1601,8702901,400
Iowa21,3403,0101,5808102,4901,6608603,150920120710
Kansas15,8102,6201,4305102,0106706802,520670120550
Kentucky30,4204,2902,5801,0104,9501,5901,1504,1401,270220960
Louisiana29,9804,2302,4908903,2901,2701,0304,6501,050210780
Maine11,0801,5207103701,4605004401,620610a340
Maryland37,2006,2702,6201,0903,9401,7801,3806,6801,3802201,320
Massachusetts44,0007,2402,7701,3805,3001,3701,8206,6901,8701801,600
Michigan66,0409,9004,7102,1008,4603,0402,59010,2302,9703802,110
Minnesota37,6505,6202,6001,3004,1102,9001,5905,7001,5101601,200
Mississippi17,8202,7101,7105102,4607005902,940710150550
Missouri39,2206,0903,0101,3105,6502,0701,5205,3201,6002501,230
Montana7,5601,0805502307505602801,230360a210
Nebraska12,3901,7909403801,2607804602,03049060390
Nevada17,5402,7601,4805601,8001,0506702,680800140560
New Hampshire10,2901,4706403401,3304604301,820530a370
New Jersey59,8409,2904,4302,0905,4202,3402,47010,7402,6303602,270
New Mexico11,5401,8509604009406704501,72045090410
New York123,43019,1708,9204,02012,7704,0305,10020,4905,2107904,440
North Carolina71,32011,3204,8902,2708,8103,8502,55011,2102,8604202,260
North Dakota4,510640360160520330190800190a130
Ohio77,01011,8005,7602,2209,9504,4402,90010,8203,4504902,620
Oklahoma24,1203,4601,9707903,1001,1808602,930960190700
Oregon26,9804,4401,8508002,9501,4201,0703,5701,220140950
Pennsylvania90,24013,6506,5002,90010,2503,7103,54013,4004,1505403,330
Rhode Island7,4801,1404802709302703001,060350a260
South Carolina35,3005,8702,6401,0304,7101,8501,2206,2801,4602401,110
South Dakota5,870830450200630440240950260a160
Tennessee42,7506,9603,4501,3006,4001,8801,5606,6301,8603001,310
Texas150,87023,88012,7105,66014,0305,7005,94021,0705,1601,4205,270
Utah14,1202,2909905407901,7006002,700530100510
Vermont4,670740290150590220200760220a170
Virginia50,5108,2503,6701,3506,1002,4101,9109,0401,9702901,750
Washington46,5007,6803,2401,4704,8602,4401,9206,7301,9702801,350
West Virginia13,2501,6901,0204102,0505304701,62059070500
Wisconsin39,9405,9202,6301,4604,3202,2301,6606,5001,7501701,380
Wyoming3,580530270100340230120550170a100
United States2,041,910316,950154,27066,890226,650104,96080,350313,78084,87013,36069,120

Estimates are rounded to nearest 10. Excludes basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates for Puerto Rico are unavailable. These are model-based estimates and should be interpreted with caution. State estimates may not sum to US total due to rounding and exclusion of state estimates of fewer than 50 cases. aFewer than 50 cases.

Please note: Estimated cases for additional cancer sites by state can be found in Supplemental Data at cancer.org/statistics or via the Cancer Statistics Center (cancerstatisticscenter.cancer.org).

©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

Page 8

Table 3. Estimated Number of Deaths for Selected Cancers by State, US, 2025

Estimates are rounded to nearest 10. State estimates may not sum to US total due to rounding and exclusion of state estimates of fewer than 50 deaths. Estimates are not available for Puerto Rico. These are model-based estimates and should be interpreted with caution. aIncludes intrahepatic bile duct. bFewer than 50 deaths. Please note: Estimated deaths for additional cancer sites by state can be found in Supplemental Data at cancer.org/statistics or via the Cancer Statistics Center (cancerstatisticscenter.cancer.org).

©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

Page 9

Table 4. Incidence Rates for Selected Cancers by State, US, 2017-2021

Lung & bronchus MaleLung & bronchus FemaleNon-Hodgkin lymphoma MaleNon-Hodgkin lymphoma FemaleProstate MaleUterine cervix Female
73.947.718.311.8121.89.4
58.650.821.715.4104.17.1
46.140.218.912.583.66.5
89.762.023.414.9119.89.3
41.234.321.715.0103.07.4
39.937.220.713.7104.46.1
59.054.124.918.0135.85.3
61.352.921.914.0136.07.2
50.242.020.412.5143.57.9
61.050.226.218.8107.79.3
68.949.021.614.5144.48.2
46.435.418.512.8106.96.7
48.443.422.915.8125.26.9
65.754.423.216.1122.87.3
83.262.822.915.8106.18.7
70.455.026.318.0131.47.8
57.949.223.115.4126.68.3
97.976.523.516.9119.09.8
75.751.223.016.4147.99.3
72.964.724.616.0109.36.4
54.947.721.814.7142.46.5
60.656.623.316.0119.84.9
65.455.422.815.6119.86.7
59.652.127.918.2122.25.5
87.856.320.813.1141.29.3
76.262.222.415.3101.68.4
47.646.622.014.0137.36.8
58.848.323.716.5128.17.5
46.844.217.912.198.28.5
63.058.624.217.5121.55.2
54.246.825.717.8149.07.3
36.530.717.312.090.88.0
59.050.925.017.6137.07.2
74.155.522.515.1134.67.0
61.453.024.116.0126.85.8
74.258.323.716.1123.47.9
73.057.620.515.3108.610.4
51.146.422.015.1101.66.7
65.453.923.516.6114.17.1
65.957.922.416.0118.66.9
70.150.720.212.8116.78.1
59.253.421.917.5130.76.3
80.460.421.414.5120.27.7
55.040.521.714.8113.19.8
28.023.023.415.1127.76.1
60.050.722.516.3111.85.7
59.546.320.313.9111.46.0
52.248.123.516.1108.66.7
85.370.923.716.5104.19.9
61.852.625.717.0127.65.9
41.039.218.914.0119.99.1
20.111.216.611.3140.311.6
60.449.122.815.7118.37.6

Rates are per 100,000, age adjusted to the 2000 US standard population using 19 age groups, and adjusted for delays in case reporting. aExcludes appendix. bBased on cases diagnosed during 2016-2020. cBased on cases diagnosed during 2015-2019. dData are not adjusted for delays. eRates do not include Puerto Rico. Data source: North American Association of Central Cancer Registries, 2024.

©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

Page 10

Table 5. Death Rates for Selected Cancers by State, US, 2018-2022

StateAll sites MaleAll sites FemaleBreast FemaleColon & rectum MaleColon & rectum FemaleLung & bronchus MaleLung & bronchus FemaleNon-Hodgkin lymphoma MaleNon-Hodgkin lymphoma FemalePancreas MalePancreas FemaleProstate Male
Alabama197.6133.220.417.611.853.330.76.33.213.410.019.9
Alaska172.3129.317.114.813.134.229.86.74.411.09.021.8
Arizona155.5117.118.814.810.229.823.55.93.412.09.017.6
Arkansas205.4140.619.818.212.356.637.16.93.813.39.519.8
California155.8116.518.814.210.227.520.06.23.611.99.220.2
Colorado150.3111.618.613.29.825.320.05.93.311.28.821.6
Connecticut161.0118.116.812.48.832.625.26.63.612.910.219.0
Delaware184.7134.522.014.810.341.530.97.24.014.510.819.7
Dist. of Columbia174.7135.724.016.012.132.422.85.73.014.012.029.7
Florida163.6120.218.614.59.937.727.05.93.412.59.116.7
Georgia182.5128.720.716.611.543.827.06.03.413.29.621.3
Hawaii144.9105.116.614.59.428.620.25.93.512.19.215.5
Idaho162.1121.019.714.410.629.223.56.24.512.29.121.2
Illinois177.2131.920.216.311.241.029.66.53.913.510.319.0
Indiana198.3141.720.317.412.350.935.67.14.514.210.620.4
Iowa179.2128.417.816.111.241.330.37.44.212.39.520.0
Kansas179.1134.419.916.511.842.531.77.34.313.89.417.9
Kentucky215.1153.021.419.613.261.043.27.44.613.410.418.2
Louisiana202.3138.222.118.512.552.431.57.03.913.911.019.8
Maine191.1135.516.714.211.145.136.26.74.313.99.620.0
Maryland167.2124.820.015.011.035.126.26.23.512.99.719.9
Massachusetts164.8118.315.212.38.634.428.16.23.613.69.918.3
Michigan186.8138.220.315.911.345.033.27.74.414.210.819.0
Minnesota167.2122.817.213.59.633.626.77.64.012.79.519.8
Mississippi223.0149.523.421.914.263.135.96.63.613.811.024.5
Missouri194.4139.320.017.211.750.636.07.04.113.910.118.4
Montana165.4122.617.714.410.131.126.05.92.911.89.220.7
Nebraska173.9128.519.517.912.037.227.56.73.713.910.219.3
Nevada166.4129.521.716.011.733.928.86.13.912.59.520.4
New Hampshire172.2124.617.613.29.436.131.06.23.513.210.019.0
New Jersey152.2118.219.113.910.231.223.55.83.312.810.016.3
New Mexico157.1114.419.315.29.825.718.15.63.511.38.519.8
New York148.7113.717.213.19.331.823.35.73.312.29.415.6
North Carolina186.2130.819.915.010.846.830.76.53.613.110.120.2
North Dakota162.1119.316.214.910.235.227.36.23.211.99.417.9
Ohio194.2137.820.216.911.548.533.27.44.114.110.519.3
Oklahoma209.4150.322.419.313.654.238.57.54.513.09.720.5
Oregon173.4131.119.114.310.334.029.17.34.212.810.121.0
Pennsylvania182.2131.619.615.611.041.629.07.04.113.710.318.5
Rhode Island173.4122.916.112.210.138.129.66.93.613.59.218.2
South Carolina190.9131.721.316.711.247.429.86.43.513.59.920.8
South Dakota177.4131.218.315.512.138.131.46.44.013.210.020.0
Tennessee201.8140.721.718.211.953.936.57.14.013.39.919.6
Texas172.0122.819.717.211.136.023.86.63.612.49.318.2
Utah137.7106.420.211.69.518.013.56.33.411.48.522.1
Vermont180.4127.616.916.09.936.628.57.23.512.810.922.0
Virginia176.0127.520.215.311.140.527.66.53.712.99.920.4
Washington167.9126.818.713.910.233.327.17.14.212.710.220.5
West Virginia211.4152.521.120.613.358.141.97.64.213.410.018.0
Wisconsin176.7127.617.913.89.937.129.07.24.013.910.221.2
Wyoming164.0129.519.916.912.130.327.26.33.712.99.719.6
Puerto Ricoa132.186.417.017.710.714.87.24.32.67.95.221.4
Total US173.2126.419.315.410.838.727.66.53.712.99.819.0

Rates are per 100,000 and age adjusted to the 2000 US standard population. aRates are for 2016-2020; they were obtained from statecancerprofiles.cancer.gov and are not included in overall US combined rates.

Data source: US Mortality Data, National Center for Health Statistics, Centers for Disease Control and Prevention, 2024. ©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

Page 11

Table 6. Probability (%) of Developing Invasive Cancer During Selected Age Intervals by Sex, US, 2018-2019, 2021

Probability is for those who are free of cancer at the beginning of each age interval. The probability of developing additional cancers and the probability of cancer death can be found in supplemental data at cancer.org/statistics. aExcludes basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. bProbabilities are for non-Hispanic White individuals only.

Data source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.9.0. Statistical Research and Applications Branch, National Cancer Institute, 2024. surveillance.cancer.gov/devcan/.

©2025, American Cancer Society, Inc., Surveillance and Health Equity Science

increased excess body weight, later age at first birth, and decreased number of childbirths. For more information on incidence trends, see Breast Cancer Statistics 2024.

Mortality trends: The female breast cancer death rate peaked in 1989 and has declined by 44% as of 2022 because of improved treatment and earlier detection through screening mammography and increased awareness, translating to approximately 517,900 fewer breast cancer deaths than would have been expected if mortality had remained at its peak. However, progress could be accelerated by eliminating racial disparities in early detection and treatment; for example, the death rate has remained unchanged over these 3 decades in American Indian and Alaska Native women and is 38% higher in Black women than in White women, despite lower incidence.

Risk factors: Increasing age and being born female are the strongest risk factors for breast cancer. Potentially modifiable factors associated with increased risk include having excess body weight or gaining weight during

adulthood (postmenopausal breast cancer only); drinking alcohol; and being physically inactive. Breastfeeding for at least one year decreases risk. Nonmodifiable factors that increase risk include a personal or family history of breast cancer, especially related to inherited genetic mutations in breast cancer susceptibility genes (e.g., BRCA1 or BRCA2). BRCA1 or BRCA2 mutations are most common among people with a strong family history of breast, ovarian, and/or some other cancers. Additional medical-related risk factors include certain benign breast conditions (e.g., atypical hyperplasia), a history of DCIS or lobular carcinoma in situ (LCIS), high breast tissue density (the amount of glandular and connective tissue relative to fatty tissue measured on a mammogram), and high-dose radiation to the chest before age 30 (e.g., for treatment of lymphoma). Reproductive and hormonal factors that increase risk include using menopausal hormone therapy (combined estrogen and progestin), previously referred to as hormone replacement therapy (HRT); a long menstrual history (menstrual periods that start early and/or end

Page 12

late in life); not having children or having a first child after age 30; high natural levels of estrogen or testosterone; and recent use of hormonal contraceptives.

Prevention: In addition to reducing risk through previously mentioned lifestyle choices, some women at high risk because of a strong family history or inherited genetic mutations may consider medicines (e.g., tamoxifen) or surgery (prophylactic mastectomy, or removal of the breasts). Women taking tamoxifen should be made aware of a small increased risk of blood clots and uterine cancer and report any abnormal vaginal bleeding, discharge, or spotting to their clinician immediately.

Early detection: Early diagnosis reduces the risk of death from breast cancer and increases treatment options. Mammography is a low-dose x-ray procedure used to detect breast cancer before it becomes symptomatic and is most effective when done regularly. However, like all screening tests, it is not perfect. Mammography can sometimes miss cancer (a falsenegative result) or appear abnormal in the absence of cancer (a false-positive result); about 12% of women who are screened have results that require further evaluation, but only 5% of women with an abnormal mammogram have cancer. Other potential harms of screening include detection and treatment of breast cancers and in situ lesions (e.g., DCIS) that would not have progressed or caused harm over the woman’s lifetime (i.e., overdiagnosis resulting in overtreatment). Although radiation exposure from mammograms is cumulative over time, it does not meaningfully increase breast cancer risk or outweigh the benefits of screening. For the American Cancer Society breast cancer screening guidelines, see page 44 and cancer.org / health-care-professionals/american-cancer-society-preventionearly-detection-guidelines/breast-cancer-screening-guidelines.

Showing pages 1–11 of 48. 6ix is still reading pages 21–48.

Attached document

Contents
  1. がんの統計 2026 CANCER STATISTICS IN JAPAN — 2026 · page 1
  2. CANCER STATISTICS IN JAPAN 72026 · page 1
  3. CONTENTS · page 2
  4. 図表編 · page 3
  5. 2025 年がん死亡数・罹患数予測 # Projection of Cancer Mortality and Incidence in 2025 · page 4
  6. ⑴ 部位別予測がん死亡数（2025年） · page 4
  7. Projected Number of Cancer Deaths by Site (2025) · page 4
  8. ⑵ 部位別予測がん罹患数（2025年） Projected Number of Cancer Incidence by Site (2025) · page 4
  9. 年齢階級別がん死亡 部位内訳 （2024年） ## Cancer Deaths by Age Group, Site Distribution (2024) · page 6
  10. Cancer mortality rate in 2024 was 379.4 for males and 262.5 for females (per 100,000 population) · page 8
  11. 都道府県別75歳未満がん年齢調整死亡率 （2024年） # Age-adjusted Cancer Mortality Rate under Age 75 by Prefectures (2024) · page 9
  12. (1) 全がん All Cancers · page 9
  13. Cancer Incidence by Age Group, Site Distribution (2021) · page 15
  14. 2021年の罹患率が高い部位は順に、男性では前立腺、大腸、肺、胃、肝臓の順、女性では乳房、大腸、肺、 胃、子宮の順 · page 17
  15. 地域がん登録における５年純生存率 （2012～2015年診断例） # 5-year Net Survival Rate, Data from Population-based Cancer Registries (Diagnosed in 2012-2015) · page 18
  16. (1) 男女計 5年純生存率 · page 18
  17. (1) 5-year Net Survival, Both Sexes · page 18
  18. (2) 临床進行度分布（主要部位） · page 19
  19. (2) Distribution of clinical stages (major sites) · page 19
  20. (3) 5-year net survival rate, by clinical stage · page 19
  21. 全国がん登録における５年純生存率（2016年診断例） 5-year Net Survival Rate, Data from National Cancer Registry (Diagnosed in 2016) · page 20
  22. 低い部位：肝および肝内胆管・胆のう・胆管、膵臓、肺、脳・中枢神経系 · page 20
  23. (1) 男女計 5年純生存率 · page 20
  24. (1) 5-year Net survival, both Sexes · page 20

Page 1

がんの統計 2026 CANCER STATISTICS IN JAPAN — 2026

CANCER STATISTICS IN JAPAN 72026

公益財団法人 がん研究振興財団 Foundation for Promotion of Cancer Research

Page 2

CONTENTS

CONTENTS Page History of Cancer Control in Japan ... 4 ~ 11 Figures and Tables 1 Projection of Cancer Mortality and Incidence in 2025 ... 14 2 Number of Deaths, by Cancer Site (2024) ... 15 3 Cancer Deaths by Age Group, Site Distribution (2024) ... 16 4 Number of Deaths by Age Group (2024) ... 17 5 Mortality Rate by Cancer Site (2024) ... 18 6 Age-adjusted Cancer Mortality Rate under Age 75 by Prefectures (2024) ... 19 ~ 23 7 Number of Incidence by Cancer Site (2021) ... 24 8 Cancer Incidence by Age Group, Site Distribution (2021) ... 25 9 Number of Incidence by Age Group (2021) ... 26 10 Incidence Rate by Cancer Site (2021) ... 27 11 5-year Net Survival Rate, Data from Population-based Cancer Registries (Diagnosed in 2012-2015) ... 28 ~ 29 12 5-year Net Survival Rate, Data from National Cancer Registry (Diagnosed in 2016) ... 30 ~ 31 13 5-year Observed Survival at the Designated Cancer Care Hospitals and other core cancer care hospitals (Diagnosed in 2014-2015) ... 32 ~ 33 14 10-year Observed Survival at the Designated Cancer Care Hospitals and other core cancer care hospitals (Diagnosed in 2012) ... 34 ~ 35 15 Cumulative Cancer Incidence/Mortality Risk ... 36 ~ 37 16 Cancer among children, adolescent and young adults ... 38 ~ 40 17 Age-adjusted Cancer Incidence Rate by Rare Cancer List (2016-2020) ... 41 ~ 42 18 Trends in Crude Mortality Rate for Leading Causes of Death (1947-2024) ... 43 19 Trends in Age-adjusted Mortality Rate for Leading Causes of Death (1950-2024) ... 44 20 Trends in Number of Deaths, by Cancer Site (1980-2024) ... 45 21 Trends in Number of Deaths, by Age Group (1980-2024) ... 46 22 Trends in Age-adjusted Mortality Rate (1979-2024) ... 47 ~ 48 23 Trends in Age-specific Mortality Rate (1980, 2000, 2024) ... 49 ~ 52 24 Trends in Number of Incidence, by Cancer Site (1980-2021) ... 53 25 Trends in Number of Incidence, by Age Group (1980-2021) ... 54 26 Trends in Age-adjusted Incidence Rate (1985-2015) ... 55 ~ 56 27 Trends in Age-specific Incidence Rate (1980, 2000, 2021) ... 57 ~ 60 28 Trends in 5-year Net Survival Rate, Data from Population-based Cancer Registry (Diagnosed in 1983-1996, 1997-1999, 2000-2002, 2003-2005, 2006-2008, 2009-2011, 2012-2015) ... 61 ~ 62 29 Smoking Prevalence ... 63 ~ 64 30 Cancer Screening Rate (2013, 2016, 2019, 2022) ... 65 ~ 68 31 International Comparisons of Cancer Screening Rates ... 69 32 Estimates of Cancer Prevalence ... 70 ~ 71 33 International Comparison of Cancer Incidence Rates and

２9 ɹSmoking Prevalence ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ 63 ʙ 64

34 ɹLife expectancy at birth (Trends of Japan and comparison in selected countries) ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ 77 35 ɹTrends in Human Development Index (HDI) and International Comparisons ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ 78

1 ɹCancer Mortality by ICD-10 Classification (2024) ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ 82 ʙ 85

6 ɹSmoking Prevalence ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ 98 7 ɹNarcotics for Medical Use ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ 99 ʙ 100 8 ɹTrends in Consumption of Tobacco, Alcohol and Food ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ101 ʙ 102 9 ɹTrends in Estimated Rate of Patients (per day) in Japan(1999-2023) ŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋŋ 103

Page 3

図表編

Figures and Tables

Page 4

最新がん統計 Cancer Statistics

１

2025 年がん死亡数・罹患数予測 # Projection of Cancer Mortality and Incidence in 2025

⑴　部位別予測がん死亡数（2025年）

Projected Number of Cancer Deaths by Site (2025)

⑵　部位別予測がん罹患数（2025年） Projected Number of Cancer Incidence by Site (2025)

がん統計予測は、死亡については人口動態統計（2024 年実測値）、罹患については全国がん登録（2021 年実測値）の性・年齢階級・部位別死亡率に、2025 年の性・年齢階級別将来推計人口を乗じて算出した。

わが国のがん死亡数の 2025 年推計値は、約 39 万 6 千人である（男性 22 万 8 千 500 人、女性 16 万 7 千人）。部位別の死亡数は、男性では肺が最も多くがん死亡全体の 24% を占め、次いで大腸（13%）、胃（11%）、膵臓（9%）、肝臓（7%）の順、女性では大腸が最も多く（16%）、次いで、肺（14%）、膵臓（13%）、乳房（10%）、胃（8％）の順となっている。

わが国のがん罹患数の 2025 年推計値は、約 102 万 3 千例である（男性57万9千800例、女性44万3千300例）。部位別では男性で前立腺（17％）、大腸（15％）、肺（15％）、胃（14％）、肝臓（4％）の順、女性で乳房（22％）、大腸（16％）、肺（10％）、胃（9％）、子宮（7％）の順となっている。

Projected numbers of cancer incidence and cancer mortality were estimated by multiplying the observed age and sexspecific numbers of cancer incidence in 2021 (National Cancer Registry) and mortality data in 2024 by the projected age and sex-specific population in 2025.

Estimated number of cancer deaths in Japan in 2025 was approximately 395,500 （228,500 males and 167,000 females）. Lung was the leading site （24%） for males, followed by colon/ rectum （13%）, stomach （11%）, pancreas （9%）, and liver （7%）. The leading site for females was colon/rectum （16%）, followed by lung （14%）, pancreas （13%）, breast （10%）, and stomach （8%）.

Estimated number of cancer incidence in Japan in 2025 was approximately 1,023,100 （579,800 for males and 443,300 for females）. Prostate was the most common cancer site （17%） for males, followed by colon/rectum （15%）, lung （15%）, stomach（14%）, and liver （4%）. The most common cancer site for females was breast （22%）, followed by colon/rectum （16%）, lung （10%）, stomach （9%）, and uterus （7%）.

資料：国立がん研究センターがん対策情報センター（https://ganjoho.jp/reg_stat/statistics/stat/short_pred.html） Source：Center for Cancer Control and Information Services, National Cancer Canter, Japan（https://ganjoho.jp/en/public/statistics/short_pred.html）

※ 表と出典は80ページ参照。See p.80 for tables and references.

Page 5

2

部位別がん死亡数（2024年） 2Number of Deaths, by Cancer Site (2024)

部位別がん死亡数 (2024年) Number of Deaths, by Cancer Site (2024)

2024年にがんで死亡した人は38万4,111人（男 性22万1,786人、女性16万2,325人） 2024年の死亡数が多い部位

384,111 persons died from cancer in 2024 (males 221,786, females 162,325)

Five leading sites in 2024 mortality

1位 1st2位 2nd3位 3rd4位 4th5位 5th備考 Memo
男性 Males肺 Lung大腸 Colon/rectum胃 Stomach膵臓 Pancreas肝臓 Liver大腸を結腸と直腸に分けた場合、結腸4位、直腸7位 Colon: 4th, rectum: 7th, when separated.
女性 Females大腸 Colon/rectum肺 Lung膵臓 Pancreas乳房 Breast胃 Stomach大腸を結腸と直腸に分けた場合、結腸3位、直腸10位 Colon: 3rd, rectum: 10th, when separated.
男女計 Both肺 Lung大腸 Colon/rectum膵臓 Pancreas胃 Stomach肝臓 Liver大腸を結腸と直腸に分けた場合、結腸3位、直腸7位 Colon: 3rd, rectum: 7th, when separated.

わが国のがん死亡は、全数調査である人口動態調查により把握されている。2024年にがんで死亡した人の数は約38万人であり、男性が女性の約1.4倍である。部位別の死亡数は、男性では肺が最も多くがん死亡全体の23.6%を占め、次いで大腸（13.0%）、胃（11.1%）、膵臓（9.2%）、肝臓（6.8%）の順、女性では大腸が最も多く（15.8%）、次いで、肺（14.3%）、膵臓（12.9%）、乳房（9.8%）、胃（8.1%）の順となっている。

yCancer deaths in Japan are surveyed by vital statistics, with % coverage. The number of cancer deaths in in Japan was approximately ,. The number of male cancer deaths was . times greater than that of female cancer deaths. In terms of cancer sites, lung was the leading site (. %) for males, followed by colon/rectum (. %), stomach (. %), pancreas ( . %), and liver ( . %). The leading site for females was colon/ rectum (. %), followed by lung (. %), pancreas (. %), breast ( . %), and stomach ( . %).

最新がん統計 Cancer Statistics

Page 6

最新がん統計 Cancer Statistics

３

年齢階級別がん死亡　部位内訳 （2024年） ## Cancer Deaths by Age Group, Site Distribution (2024)

がん死亡の部位内訳を年齢階級別に見ると、男性では、40歳以上で胃、大腸、肝臓など消化器系のがんが5～6割を占め、70歳以上では肺がんと前立腺がんの割合が大きくなる。女性では、40歳代で乳がん、子宫がん、卵巣がんの死亡が約半分を占めるが、高齢になるほどその割合は小さくなり、消化器系と肺がんの割合が大きくなる。男女とも39歳以下では、他の年齡階級に比べて、消化器系および肺がんの占める割合が小さく、白血病の占める割合が大きい。

yThe site distribution of cancer mortality varied across age groups. For males aged years or older, cancer of the intestine (stomach, colon/rectum, liver etc.) accounted for -% of cancer mortality, and the proportion of lung and prostate cancer was large among years or older. For females aged - years, approximately half of cancer deaths were accounted for by cancer of the breast, uterus, and ovary, while the proportion of those sites decreased and the proportion of cancer in intestine and lung increased with age. For both males and females under years old, the proportion of cancer of the intestine and lung was small and the proportion of leukemia was large, as compared with older age groups.

Show more of the filing

Page 7

4

がん死亡　年齢階級内訳（2024年） Number of Deaths by Age Group (2024)

年齢階級別の死亡者数は、男女ともに70歳代から大きく増加し、80歳代をピークにその後の年代では減少している。男性では80～84歳が最も多く44,970人であり、女性では85～89歳が最も多く29,249人であった。

yFor both males and females, cancer mortality by age group showed a significant increase in the s, peaked in the s, and then decreased thereafter.

yFor males, mortality was highest in the – age group, with , deaths, while For females, it was highest in the – age group, with , deaths.

最新がん統計 Cancer Statistics

Page 8

最新がん統計 Cancer Statistics

5

部位別がん死亡率（2024年） Mortality Rate by Cancer Site (2024)

人口10万对 Rate per 100,000

2024年のがんの死亡率は男性379.4、女性262.5（人口10万対）

2024年の粗死亡率が高い部位は、男性では肺、大腸、胃、膵臓、肝臓の順、女性では大腸、肺、膵臓、乳房、 胃の順

Cancer mortality rate in 2024 was 379.4 for males and 262.5 for females (per 100,000 population)

The cancer site with the highest mortality rate in 2024 was lung for males, followed by colon/rectum, stomach, pancreas, and liver; colon/rectum was the highest for females, followed by lung, pancreas, breast, and stomach.

わが国の2024年のがん死亡率（人口10万人当たり何例死亡するか）は、男性で約379、女性では約263である。多くの部位で男性が女性より死亡率が高い。特に、口腔·咽頭、食道、肝臓、喉頭、肺、膀胱では男性の死亡率が女性の約2倍以上である。一方、甲状腺では女性が男性より死亡率が高い。部位别死亡率では、男性は肺、大腸、胃、膵臓、肝臓の順に高く、女性は大腸、肺、膵臓、乳房、胃の順に高い。

yCancer mortality rate (annual number of deaths per , population) in Japan in was approximately for males and for females. The mortality rates were higher among males than females for many cancer sites, especially oropharynx, esophagus, liver, larynx, lung, and bladder (approximately double or more). On the other hand, female mortality rates were higher than male for thyroid. The cancer sites with the highest mortality rate in were lung, colon/rectum, stomach, pancreas, and liver for males, colon/rectum, lung, pancreas, breast, and stomach, for females.

Page 9

6

都道府県別75歳未満がん年齢調整死亡率 （2024年） # Age-adjusted Cancer Mortality Rate under Age 75 by Prefectures (2024)

(1) 全がん All Cancers

(2) 食道がん Esophagus

75歳未満の年齢調整死亡率（2024年）で比較した場合、全がん死亡率が低い上位5県は、

男女計長野県、滋賀県、広島県、福井県、岐阜県男性長野県、滋賀県、岐阜県、静岡県、東京都女性滋賀県、福井県、石川県、広島県、長野県

yThe five prefectures with lowest age-adjusted cancer mortality rate under age in were as follows. Both sexes Nagano, Shiga, Hiroshima, Fukui and Gifu Males Nagano, Shiga, Gifu, Shizuoka and Tokyo Females Shiga, Fukui, Ishikawa, Hiroshima and Nagano

注）基準人口は昭和60年（1985年）モデル人口を使用 Note: Standardized to the 1985 Japanese model population.

※ 表と出典は80ページ参照。See p.80 for tables and references for all-cancer mortality.

最新がん統計 Cancer Statistics

Page 10

最新がん統計 Cancer Statistics

(3) 胃がん Stomach

(4) 结腸がん Colon

75歳未满年齡調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000) 女性 Females

(5) 直腸がん Rectum

がん死亡率が高い上位5県は、

男女計 青森県、秋田県、北海道、和歌山県、長崎県男性 青森県、秋田県、和歌山県、長崎県、北海道

である。全がん死亡率が高いこれらの都道府県は、主要5部位（胃、大腸、肝臓、肺、乳房）の死亡率も高い傾向がある。

75歲未満年齡調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000) 女性 Females

yThe five prefectures with highest age-adjusted cancer mortality rate under age in were as follows.

yBoth sexes Aomori, Akita, Hokkaido, Wakayama, and Nagasaki yMales Aomori, Akita, Wakayama, Nagasaki and Hokkaido yFemales Aomori, Hokkaido, Akita, Nagasaki and Iwate

yThose five prefectures with high all-cancer mortality rate also tended to show high mortality rates for major five cancer sites (stomach, colon/rectum, liver, lung, and breast)

Page 11

(6) 肝臓がん Liver

(7) 胆のう·胆管がん Gallbladder and Bile Ducts

75歲未満年齡調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000)

(8) 膵臓がん Pancreas

部位別で死亡率の地域差が明らかな部位は、

[胃がん] 男女とも東北地方の日本海側で死亡率が高い。 [肝臓がん] 男女とも西日本で死亡率が高い。これは、西日本でC型肝炎ウイルスの感染者割合が高いことに関連している。

yGeographic patterns of site-specific cancer mortality were as follows.

［Stomach］Higher mortality rate for both sexes was seen in the Western part of Tohoku district.

［Liver］Higher mortality rate for both sexes was seen in Western Japan. This is associated with higher prevalence of hepatitis C virus infection in Western Japan.

最新がん統計 Cancer Statistics

Page 12

最新がん統計 Cancer Statistics

(9) 肺がん Lung

(10) 乳がん Breast女性

75歲未满年齡調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000)

(11) 子宮がん Uterus 75歳未满年齢調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000) 女性 Females

(12) 卵巣がん Ovary 75歳未满年齢調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000) 女性 Females

[肺がん] 男女とも近畿地方および北海道で死亡率が高い。 [乳がん（女性）] 东日本で死亡率が高い。

(13) 前立腺がん Prostate男性 Males

［Lung］ Higher mortality rate for both sexes was seen in the Kinki and Hokkaido districts. ［Breast (females)］ Higher mortality rate was seen in the Eastern Japan.

Page 13

(14) 悪性リンパ腫 Malignant Lymphoma

75歲未满年龄調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000) 女性 Females

(15) 白血病 Leukemia

(16) 大腸がん Colon/rectum

[前立腺がん] 東北地方北部で死亡率が高い。

[白血病] 男女とも九州・沖縄地方で死亡率が高い。これは、九州・沖縄地方で成人T細胞白血病ウイルスI型（HTLV-I）の感染者割合が高いこと関連している。

75歳未満年齡調整死亡率（人口10万対） Age-adjusted mortality rate under age 75 (per 100,000) 女性 Females

［Prostate］Higher mortality rate was seen in the Northern part of the Tohoku district.

［Leukemia］Higher mortality rate for both sexes was seen in the Kyushu and Okinawa islands. This is associated with higher prevalence of human T-cell leukaemia virus type I infection in those regions.

最新がん統計 Cancer Statistics

Page 14

最新がん統計 Cancer Statistics

7

部位別がん罹患数（2021年） Number of Incidence by Cancer Site (2021)

2021年に新たに診断されたがんは98万8,900例（男性55万5,918例、女性43万2,982例） 2021年の罹患数が多い部位

988,900 new cancer cases were diagnosed in 2021 (males 555,918, females 432,982) Five leading sites in 2021 incidence

わが国のがん罹患（新たにがんと診断されること）は、2016年から全国がん登録で把握されている。それによると、2021年に新たに診断されたがんは約99万例であり、男性が女性の約1.3倍である。部位別の罹患数は、男性では前立腺が最も多くがん罹患全体の $17.2%$ を占め、次いで大腸（$15.5%$）、肺（$14.9%$）、胃（$13.8%$）、肝臓（$4.3%$）の順、女性では、乳房が最も多く $22.8%$ 、次いで、大腸（$15.8%$）、肺（$9.6%$）、胃（$8.3%$）、子宫（$7.0%$）の順となっている。

yCancer incidence cases in Japan were collected by the National Cancer Registry system. The number of cancer incidence cases in in Japan was approximately ,. The number of male cancer incidence was . times as large as that of females. In terms of cancer sites, the prostate was the leading site (. %) for males, followed by colon/rectum (. %), lung (. %), stomach (. %), and liver ( . %). The leading cancer site for females was breast (. %), followed by colon/rectum (. %), lung ( . %), stomach ( . %), and uterus ( . %).

Page 15

8

Cancer Incidence by Age Group, Site Distribution (2021)

がん罹患の部位内訳を年齢階級別に見ると、男性では、40歳以上で胃、大腸、肝臓などの消化器系のがんが4～5割を占め、70歳以上では肺がんと前立腺がんの割合が大きくなる。女性では、40歳代で乳がんが約50%、子宫がんと卵巣がんが合わせて約20%を占めるが、高齢になるほどそれらの割合は小さくなり、消化器系（胃、大腸、肝臓など）と肺がんの割合が大きくなる。男性の39歳以下では、40歳以上に比べて、消化器系および肺がんの占める割合が小さく、白血病の占める割合が大きい。女性の39歳以下では、40歳以上に比べて、子宫頸部の割合が大きい。

yThe site distribution of cancer incidence varied across age groups. For males aged years or older, cancer of the intestine (stomach, colon/rectum, liver etc.) accounted for -% of cancer incidence, and the proportion of lung and prostate cancer was large among years or older. For females aged - years old, approximately half of cancer incidence cases were accounted for by cancer of the breast, and approximately % were accounted for by uterus and ovary. The proportion of those three sites decreased with age and the proportion of intestine (e.g. stomach, colon/rectum, liver) and lung increased instead. For males under age , the proportion of intestine and lung was smaller and the proportion of leukaemia was larger, as compared with years or older age groups. For females under age , the proportion of cervix uteri was greater than that of females aged years or older.

※ 表と出典は81ページ参照。See p.81 for tables and references.

最新がん統計 Cancer Statistics

Page 16

最新がん統計 Cancer Statistics

9

がん罹患　年齢階級内訳（2021年） Number of Incidence by Age Group (2021)

年齢階級別の罹患者数は、男女ともに60歳代前後で大きく增加し、70歳代をピークにその後の年代では減少している。

男女ともに70～74歳が最も多く、男性では120,374人、女性では64,837人であった。

また、女性は男性と比較して、15～59歳の年代で罹患数が多い。

yFor both males and females, cancer incidence by age group showed a significant increase around the s, peaked in the s, and then decreased thereafter.

yIn the - age group for both males and females, the number of incidence was highest, with , cases for males and , cases for females.

yAdditionally, compared to males, females had a higher incidence in the - age range.

Page 17

部位別がん粗罹患率（2021年） 10Incidence Rate by Cancer Site (2021)

2021年のがんの罹患率は男性911.1、女性671.5（人口10万対）

2021年の罹患率が高い部位は順に、男性では前立腺、大腸、肺、胃、肝臓の順、女性では乳房、大腸、肺、 胃、子宮の順

Cancer incidence rate in 2021 was 911.1 for males, 671.5 for females (per 100,000 population) The cancer sites with the highest incidence rate in 2021 was prostate for males, followed by colon/rectum, lung, stomach, and liver ; breast for females, followed by colon/rectum, lung, stomach, and uterus.

2021年のがんの罹患率（人口10万人当たり何例新たに诊断されるか）は男性で911.1、女性で671.5である。死亡と同様に多くの部位で男性が女性より罹患率が高い。特に、口腔・咽頭、食道、胃、肝臓、喉頭、肺、膀胱、肾臓で男性の罹患率が女性の2倍以上である。甲状腺では女性が男性より罹患率が高い。部位別罹患率では、男性では前立腺、大腸、肺、胃、肝臓の順に高く、女性では乳房、大腸、肺、胃、子宫の順に高い。

yCancer incidence rate (annual number of newly diagnosed cases per , population) in Japan in was . for males and . for females. The incidence rates were higher among males than females, especially for oropharynx, esophagus, stomach, liver, larynx, lung, bladder, and kidney (over twice). On the other hand, female incidence rates were higher than male for thyroid. The cancer sites with the highest incidence rate in was prostate for males, followed by colon/rectum, lung, stomach, and liver ; breast for females, followed by colon/rectum, lung, stomach, and uterus.

最新がん統計 Cancer Statistics

Page 18

最新がん統計 Cancer Statistics

11

地域がん登録における５年純生存率 （2012～2015年診断例） # 5-year Net Survival Rate, Data from Population-based Cancer Registries (Diagnosed in 2012-2015)

(1) 5年純生存率 男女計 15歲～99歳 (5-year Net Survival, Both Sexes, 15-99 years old)

地域がん登録における2012～2015年診断例のAYA・成人の純生存率が

高い部位：喉頭、皮膚、乳房（女性）、子宮頸部、子宮体部、前立腺、甲状腺

低い部位：肝および肝内胆管、胆のう・胆管、膵臓、肺、脳・中枢神経系、白血病

5-year net survival rates among AYA and adults diagnosed in 2012-2015 from 44 Population based Cancer Registries were

high for : larynx, skin, breast (female), cervix uteri, corpus uteri, prostate and thyroid

low for : liver, gallbladder and bile ducts, pancreas, lung, brain and nervous system, leukemia

(1) 男女計 5年純生存率

44都道府県（北海道、青森県、岩手県、宮城県、秋田県、山形県、福島県、茨城県、栃木県、群馬県、埼玉県、千葉県、東京都、神奈川県、新潟県、石川県、福井県、山梨県、长野県、岐阜県、愛知県、三重県、滋賀県、京都府、大阪府、兵庫県、奈良県和歌山県、鳥取県、島根県、岡山県、広島県、山口県、徳島県、香川県、爱媛県、高知県、福岡県、佐賀県、長崎県、熊本県、大分県、鹿児島県、沖縄県）の地域がん登録において、2012-2015年に诊断された患者 1 ）の5年純生存率を見ると、胃、結腸、直腸では、63%～68%に分布した。皮膚、乳房、前立腺、甲状腺では、85%以上と生存率が高く、肝および肝内胆管、胆のう·胆管、膵臓、肺、脳·中枢神经系、白血病では40%未満と、生存率が低い。

(1) 5-year Net Survival, Both Sexes

yAccording to data from population-based cancer registries in prefectures (Hokkaido, Aomori, Iwate, Miyagi, Akita, Yamagata, Fukushima, Ibaraki, Tochigi, Gunma, Saitama, Chiba, Tokyo, Kanagawa, Niigata, Ishikawa, Fukui, Yamanashi, Nagano, Gifu, Aichi, Mie, Shiga, Kyoto, Osaka, Hyogo, Nara, Wakayama, Tottori, Shimane, Okayama, Hiroshima, Yamaguchi, Tokushima, Kagawa, Ehime, Kochi, Fukuoka, Saga, Nagasaki, Kumamoto, Oita, Kagoshima, and Okinawa), The -year net survival rates for stomach, colon and rectum cancers diagnosed in – ranged from % to %. Cancer of skin, breast, prostate and thyroid showed higher survival rates (> %), while liver, gallbladder and bile duct, pancreas, lung, brain and nervous system and leukemia showed lower survival rates (< %).

（注）1）死亡票のみの患者、悪性以外、年齢不詳および性別不詳を除く。 Note: 1) Excluding the following cases: death certificate only, non-malignant, age unknown, or sex unknown.

Page 19

(2) 临床進行度分布 男女計 15歲～99歳 Distribution of Clinical Stages (Both Sexes, 15-99 years old)

(3) 臨床進行度別5年純生存率 男女計 15歲～99歳 5-year Net Survival Rate by Clinical Stages (Both Sexes, 15-99 years old)

(2) 临床進行度分布（主要部位）

44都道府県（北海道、青森県、岩手県、宮城県、秋田県、山形県、福島県、茨城県、栃木県、群馬県、埼玉県、千葉県、東京都、神奈川県、新潟県、石川県、福井県、山梨県、长野県、岐阜県、愛知県、三重県、滋賀県、京都府、大阪府、兵庫県、奈良県和歌山県、鳥取県、島根県、岡山県、広島県、山口県、徳島県、香川県、爱媛県、高知県、福岡県、佐賀県、長崎県、熊本県、大分県、鹿児島県、沖縄県）の地域がん登録において2012-2015年に診断された患者の診断時の臨床進行度分布をみると、がんが原発臓器·組織に「限局」しているもの割合は、胃、結腸、直腸、肝および肝内胆管、乳房、子宫頸部の各がんでは $43\sim 58%$ 、子宫体部、前立腺では $60%$ 以上と比較的高く、肺では $32%$ 以上低い。（3）臨床進行度別5年純生存率

臨床進行度別の5年純生存率をみると、「限局」の生存率は、胃、結腸、直腸、乳房（女性）、子宫頸部、子宫体部、前立腺では90%以上に分布し良好だが、肺では77.8%、肝および肝内胆管では49.7%と比較的不良である。領域リンパ節に転移があるか隣接臓器·組織に浸潤している「領域」の生存率は、胃、結腸、直腸、子宫、前立腺では49～97%に分布したが、肝および肝内胆管では12%、肺では33%と不良である。さらに進展した「遠隔」の生存率は、直腸、乳房、子宫頸部および前立腺を除けばいずれも20%未満と極めて不良である。

(2) Distribution of clinical stages (major sites)

yAccording to data from population-based cancer registries of patients diagnosed in - in prefectures (Hokkaido, Aomori, Iwate, Miyagi, Akita, Yamagata, Fukushima, Ibaraki, Tochigi, Gunma, Saitama, Chiba, Tokyo, Kanagawa, Niigata, Ishikawa, Fukui, Yamanashi, Nagano, Gifu, Aichi, Mie, Shiga, Kyoto, Osaka, Hyogo, Nara, Wakayama, Tottori, Shimane, Okayama, Hiroshima, Yamaguchi, Tokushima, Kagawa, Ehime, Kochi, Fukuoka, Saga, Nagasaki, Kumamoto, Oita, Kagoshima, and Okinawa), cancer classified as llocalizedz accounted for - % for stomach, colon, rectum, liver, breast, cervix uteri, exceeded % for corpus uteri, prostate, and % for lung.

(3) 5-year net survival rate, by clinical stage

yThe -year net survival rates for llocalizedz cancer were high (> %) for stomach, colon, rectum, breast (female), cervix uteri, corpus uteri, and prostate and . % for lung and relatively low . % for liver. The survival rates of lregionalz cancers with metastases to regional lymph nodes or infiltration ranged from % to % for stomach, colon, rectum, uterus, and prostate, % for liver, and % for lung. The survival rates of all the ldistantz cancers, excluding rectum, breast, cervix uteri and prostate, were lower than %.

最新がん統計 Cancer Statistics

Page 20

最新がん統計 Cancer Statistics

12

全国がん登録における５年純生存率（2016年診断例） 5-year Net Survival Rate, Data from National Cancer Registry (Diagnosed in 2016)

(1) 5年純生存率 男女計 15歲～99歳 (5-year Net Survival, Both Sexes, 15-99 years old)

全国がん登録における2016年診断例のAYA・成人の純生存率が

高い部位：喉頭、皮膚、乳房(女性)、子宮頸部、子宮体部、前立腺、甲状腺

低い部位：肝および肝内胆管・胆のう・胆管、膵臓、肺、脳・中枢神経系

5-year net survival rates among AYA and adults diagnosed in 2016 in the National Cancer Registry were high for : larynx, skin, breast (female), cervix uteri, corpus uteri, prostate and thyroid low for : liver, gallbladder and bile ducts, pancreas, lung, and brain and nervous system

(1) 男女計 5年純生存率

全国がん登録において、2016年に诊断されたAYA·成人の患者の5年純生存率を見ると、胃で64.0%、結腸で67.4%、直腸で68.4%、肝および肝内胆管で33.4%、肺で37.7%、女性乳房で88.0%、子宫頭部で71.8%、子宫体部で79.0%、前立腺で92.1%であった。

皮膚、乳房、前立腺、甲状腺では、85%以上と生存率が高く、肝および肝内胆管、胆のう·胆管、膵臓、肺、脳·中枢神经系では40%未満と生存率が低かった。

(1) 5-year Net survival, both Sexes

yIn the National Cancer Registry, the -year net survival for AYA and adults diagnosed in was . % for stomach, . % for colon, . % for rectum, . % for liver and intrahepatic bile ducts, . % for lung, . % for female breast, . % for cervix uteri, . % for corpus uteri, and . % for prostate.

yNet survival is high (> %) for skin, breast, prostate, and thyroid, and low (< %) for liver, gallbladder and bile ducts, pancreas, lung, and brain and nervous system.

Showing pages 1–20 of 68. 6ix is still reading pages 21–68.

View original source (Business Wire)Company analysis

Earlier from Novocure

All Novocure news releases